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a b s t r a c t
Lloviu virus (LLOV), a phylogenetically divergent ﬁlovirus, is the proposed etiologic agent of die-offs of
Schreibers's long-ﬁngered bats (Miniopterus schreibersii) in western Europe. Studies of LLOV remain
limited because the infectious agent has not yet been isolated. Here, we generated a recombinant
vesicular stomatitis virus expressing the LLOV spike glycoprotein (GP) and used it to show that LLOV GP
resembles other ﬁlovirus GP proteins in structure and function. LLOV GP must be cleaved by endosomal
cysteine proteases during entry, but is much more protease-sensitive than EBOV GP. The EBOV/MARV
receptor, Niemann–Pick C1 (NPC1), is also required for LLOV entry, and its second luminal domain is
recognized with high afﬁnity by a cleaved form of LLOV GP, suggesting that receptor binding would not
impose a barrier to LLOV infection of humans and non-human primates. The use of NPC1 as an
intracellular entry receptor may be a universal property of ﬁloviruses.
& 2014 Elsevier Inc. All rights reserved.
1. Introduction
Members of the family Filoviridae have non-segmented negative-
strand RNA genomes and produce ﬁlamentous enveloped particles.
Until recently, all known ﬁloviruses belonged to one of two genera –
Ebolavirus or Marburgvirus (Kuhn et al., 2011). Three ebolaviruses
[Ebola virus (EBOV), Bundibugyo (BDBV), and Sudan virus (SUDV)],
and two marburgviruses [Marburg virus (MARV) and Ravn virus
(RAVV)] are associated with highly lethal outbreaks of ﬁlovirus
disease in humans and non-human primates, and are endemic in
equatorial regions of the African continent (recently reviewed in
Feldmann and Geisbert, 2011; Hartman et al., 2010; MacNeil et al.,
2011; Paessler and Walker, 2013; Pourrut et al., 2005). One
ebolavirus, Reston virus (RESTV), is thought to be avirulent in
humans (Morikawa et al., 2007), but has been associated with
multiple incidents of ﬁlovirus disease in monkeys exported from
the Philippines to the US or Europe for research (Miranda et al.,
2002; Rollin et al., 1999). More recently, RESTV was shown to
circulate in domesticated pigs in the Philippines (Barrette et al.,
2009). There are currently no FDA-approved vaccines or thera-
peutics to prevent or treat ﬁlovirus infections.
Bats are long-suspected ﬁlovirus reservoirs (Leroy et al., 2009;
2005; Olival and Hayman, 2014; Pourrut et al., 2009; Swanepoel
et al., 1996), but conclusive evidence for their role in the ecology of
ﬁloviruses was lacking until recently, when infectious MARV and
RAVV were found to circulate in healthy Egyptian rousettes (Rousettus
aegyptiacus) (Amman et al., 2012; Towner et al., 2009). Infectious
EBOV has not yet been isolated from bats. However, EBOV-speciﬁc
antibodies and viral nucleic acids have been detected in African fruit
bats belonging to three species (Hypsignathus monstrosus, Epomops
franqueti, and Myonycteris torquata) (Leroy et al., 2005).
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In the early 2000s, massive bat die-offs of Schreibers's long-
ﬁngered bats (Miniopterus schreibersii) occurred throughout the
Iberian peninsula. Investigators working with bat carcasses from
Cueva del Lloviu, Spain, were able to detect ﬁlovirus-like nucleic
acids in the lung and spleen by PCR (Negredo et al., 2011). While
attempts to isolate infectious virus from these carcasses were
unsuccessful, a near-complete ﬁlovirus genome, equally divergent
from those of ebolaviruses and marburgviruses (E50% nucleotide
sequence identity) was assembled (Negredo et al., 2011). Because
this viral genome was detected only in carcasses of Schreibers's
long-ﬁngered bats and not in healthy long-ﬁngered or mouse-
eared myotis (Myotis myotis), the authors proposed that
a new ﬁlovirus-like agent, named Lloviu virus (LLOV) after the
site of detection, may have been responsible for the bat die-offs
(Negredo et al., 2011). The Internal Committee of Taxonomy of
Viruses (ICTV) placed LLOV in a new genus, Cuevavirus, within the
family Filoviridae (Adams et al., 2014; Kuhn et al., 2010). LLOV
represents the ﬁrst ﬁlovirus discovered in Europe that was not
transported there from an endemic area in Africa or Asia.
Since LLOV is phylogenetically divergent from ebolaviruses and
marburgviruses, was discovered in a new geographic area, and may
be virulent in bats, it is possible that it differs from other known
ﬁloviruses with regard to fundamental mechanisms of infection,
multiplication, and in vivo pathogenesis. However, the lack of an
isolate has severely impeded the study of LLOV. In this study,
we exploited a vesicular stomatitis virus (VSV)-based surrogate
system to investigate the structural and functional properties of the
presumptive envelope glycoprotein (GP) of LLOV, and the mechan-
ism by which it mediates viral entry into the cytoplasm of host cells.
While this manuscript was in preparation, a study describing
some entry-related properties of LLOV GP was published (Maruyama
et al., 2013). That study employed vesicular stomatitis virus (VSV)
single-cycle pseudotypes bearing LLOV GP. Here, we used reverse
genetics to generate a recombinant VSV containing LLOV GP that is
capable of multiple rounds of multiplication in tissue culture, thus
providing a robust model for early steps in infection by the authentic
virus. Our ﬁndings are in agreement with those of Maruyama and co-
workers, and extend them in several important respects. Most
signiﬁcantly, we demonstrate that the late endosomal membrane
protein Niemann–Pick C1 (NPC1) is a critical entry receptor for
LLOV that binds directly and with high afﬁnity to a cleaved form of
LLOV GP.
2. Results
2.1. Generation of an infectious recombinant vesicular stomatitis
virus expressing the LLOV transmembrane envelope glycoprotein
To study the mechanism by which LLOV enters host cells, we
focused on the LLOV GP gene, which is predicted to encode a single
transmembrane glycoprotein and multiple secreted glycoproteins
homologous to their counterparts from African and Asian ﬁlo-
viruses (Figs. 1 and S1) (Negredo et al., 2011). Using reverse
genetics, we generated the ﬁrst recombinant vesicular stomatitis
virus (rVSV) expressing the LLOV transmembrane glycoprotein GP
in place of the orthologous VSV entry glycoprotein, G. The rescued
virus was ampliﬁed in Vero cells, and the integrity of the LLOV GP
gene in multiple viral clones was veriﬁed by RT-PCR and sequen-
cing. We found that rVSV-GP-LLOV was competent to form plaques
on Vero cell monolayers, and to replicate in these cells at levels
comparable to rVSVs bearing other ﬁlovirus glycoproteins (Fig. 1A)
(Carette et al., 2011; Wong et al., 2010).
Because the LLOV glycoprotein in these virus particles was
not detected by several EBOV- and MARV GP-speciﬁc antibodies,
we raised a rabbit polyclonal antiserum against a sequence in
the N-terminal region of the LLOV GP1 subunit (residues
83–97; TKRWGFRSDVIPKIV). Western blotting of concentrated
Fig. 1. LLOV GP is incorporated into VSV particles and ﬁlovirus-like particles, and is competent to mediate cell entry. (A) Vero cells were exposed to recombinant VSVs
(rVSVs) expressing eGFP, and VSV G or different ﬁlovirus glycoproteins. Infected cells were visualized by ﬂuorescence microscopy at 12–16 h post-infection. Averages7SD
(n¼4) are shown. (B) Incorporation of LLOV GP into rVSVs was determined by SDS-PAGE and western blotting with an LLOV GP1-speciﬁc antiserum. (C) Vero E6 cells
generating ﬁlovirus-like particles (VLPs) consisting of EBOV VP40 and LLOV GP were visualized by transmission electron microscopy. Red arrows, ﬁlamentous VLPs released
from cells. Blue arrows, spike-like projections from the surface of a VLP, likely corresponding to LLOV glycoprotein spikes.
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rVSV-GP-LLOV particles with this antiserum detected a E130K
polypeptide that resembles the GP proteins of other ﬁloviruses in
molecular weight and presumptively contains the LLOV GP1
subunit (Fig. 1B) (Sanchez et al., 1998; Volchkov et al., 2000).
Finally, to test whether LLOV GP can be incorporated into
ﬁlovirus-like particles (Martin-Serrano et al., 2001; Noda et al.,
2002), we co-transfected 293T human embryonic kidney cells with
plasmids encoding GP and the LLOV matrix protein VP40. Examina-
tion of thin sections of these cells by transmission electron micro-
scopy revealed both particles with the characteristic ﬁlamentous
morphology of ﬁlovirions and spherical particles. Each type of
particle bore a halo of spike-like structures at its surface that was
absent in particles produced by cells expressing only VP40 (Fig. 1C),
suggesting that these surface spikes are composed of LLOV GP.
Taken together, these results indicate that the ﬁlovirus-like gen-
omes detected in the Schreibers's long-ﬁngered bats from Cueva del
Lloviu encode a functional viral spike glycoprotein.
2.2. The LLOV GP precursor is processed into GP1 and GP2 subunits
by the proprotein convertase furin
Filovirus GP proteins are synthesized as a precursor polypep-
tide, preGP, which trimerizes in the endoplasmic reticulum (ER)
(Feldmann et al., 1991; Jeffers et al., 2002; Sanchez et al., 1998;
Volchkov et al., 2000; 1998; reviewed in Feldmann et al., 2001).
Following its transport to the trans-Golgi network (TGN), preGP is
post-translationally cleaved to GP1þGP2 subunits by the propro-
tein convertase furin (Fig. S1) (Sanchez et al., 1998; Volchkov et al.,
1998). GP1 and GP2 remain associated through extensive non-
covalent interactions and an inter-subunit disulﬁde bond, and
perform distinct functions during cellular entry (Jeffers et al.,
2002; Lee et al., 2008). While GP1 mediates viral attachment to
the host cell, binds to the endosomal ﬁlovirus receptor NPC1, and
regulates the conformation of GP2, GP2 catalyzes the fusion of
viral and cellular membranes (see Miller and Chandran, 2012 for a
recent review).
Furin, a ubiquitous subtilisin-like endoprotease, cleaves its
target proteins immediately after polybasic sites (consensus:
R-X-K/R-R↓) (reviewed in Seidah et al., 2013). We identiﬁed
a single candidate cleavage site for furin in the predicted amino
acid sequence of LLOV GP (residues 505–508; RRRR). To experi-
mentally assess whether LLOV GP undergoes furin cleavage, we
exposed control or furin-deﬁcient Chinese hamster ovary cell lines
to rVSVs containing EBOV or LLOV GP. Virus-containing super-
natants from control or furin-deﬁcient FD11 CHO cells (Gordon
et al., 1995) were harvested at 48 and 72 h post-infection,
respectively, and the GP1 subunit in progeny virus particles was
detected by western blotting (Fig. 2A). EBOV GP1 produced by
furin-deﬁcient FD11 cells migrated as a larger species than that
produced by control cells, indicating that it underwent furin-
dependent preGP -GP1þGP2 cleavage, as shown previously
(Volchkov et al., 1998). Similarly, LLOV GP1 produced by furin-
deﬁcient and control cells migrated at E140 and E110 kDa,
respectively (Fig. 2A), providing evidence that the LLOV GP pre-
cursor, like the GP proteins of all other known ﬁloviruses, is a
substrate for furin cleavage.
2.3. LLOV GP is subject to extensive N-linked glycosylation and is
predicted to contain a central mucin-like domain
Nascent ﬁlovirus glycoproteins undergo extensive N-linked and
O-linked glycosylation within the secretory pathway of infected
cells (Feldmann et al., 1991; Jeffers et al., 2002; Lee et al., 2008;
Sanchez et al., 1998; reviewed in Feldmann et al., 2001). Sequence-
based analyses of likely glycosylation sites suggested that LLOV GP
resembles other ﬁlovirus GP proteins in this regard (Fig. S1). First,
LLOV GP was predicted to contain a number of N-linked sites
distributed throughout the protein. Alignments with EBOV and
MARV GP sequences identiﬁed sequons conserved among all three
proteins; these were located within the regions of GP showing the
highest degree of overall sequence (and likely, structural) con-
servation (N-terminal region of GP1, C-terminal region of GP2).
Second, like EBOV and MARV GP, LLOV GP was predicted to
undergo O-linked glycosylation at a large number of contiguous
sites within a central region of the protein that is also the least
conserved among ﬁloviruses in amino acid sequence. These shared
features–extensive O-linked glycosylation concentrated within a
central, highly variable region of GP–strongly argue that LLOV GP,
like the GP proteins of all known African and Asian ﬁloviruses,
contains a mucin-like domain (Muc). Muc is proposed to shield GP
from host immune detection, and may also promote viral adhesion
to speciﬁc host cells (Alvarez et al., 2002; Francica et al., 2010; Lee
and Saphire, 2009; Marzi et al., 2007; Reynard et al., 2009).
To experimentally examine N-linked glycosylation in LLOV GP,
we exposed concentrated rVSV particles containing EBOV or LLOV
GP to protein N-glycosidase F (PNGase F), which enzymatically
removes most N-linked glycans (see Materials and Methods
for details). Virus particles treated with PNGase F increased the
electrophoretic mobility of LLOV GP1 from E130 kDa to E70 kDa
(Fig. 2B). These ﬁndings provide evidence that LLOV GP resembles
other ﬁlovirus GP proteins in the number and distribution of
N-linked glycosylated sites, and in presumptively containing a
highly O–glycosylated central mucin-like (Muc) domain.
2.4. LLOV GP requires endosomal acid pH to mediate viral entry
Filoviruses enter host cells through a macropinocytosis-like
pathway, and are then trafﬁcked to late endosomes (Mulherkar
et al., 2011; Nanbo et al., 2010; Saeed et al., 2010) (Mulherkar and
Chandran, unpublished). These endocytic compartments provide
acidic conditions that are proposed to play multiple crucial roles in
ﬁlovirus entry. First, endosomal cysteine cathepsins, which cleave
ﬁlovirus glycoproteins to expose the NPC1 receptor-binding site in
GP1 (Chandran et al., 2005; Côté et al., 2011; Miller et al., 2012),
require endo/lysosomal acid pH for their maturation and activity
Fig. 2. The LLOV GP precursor is cleaved by furin into GP1 and GP2 subunits, and is
extensively N-glycosylated. (A) rVSV-LLOV GP and rVSV-EBOV GPΔMuc produced in
WT CHO cells or the FD11 CHO cell line lacking furin (Furin0) were subjected to
reducing SDS-PAGE, and their GP1 subunits were visualized by western blotting
with peptide-speciﬁc antisera. (B) rVSV-LLOV GP was incubated with protein
N-glycosidase F (PNGase F) to remove N-linked glycans, and GP1 was visualized
by western blotting.
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(reviewed in Turk et al., 2012). Second, endosomal acid pH is
proposed to be necessary for multiple steps in the GP-catalyzed
membrane fusion reaction that effects viral escape into the
cytoplasm (reviewed in Miller and Chandran, 2012; White et al.,
2008).
To examine the requirement of endosomal acid pH for LLOV
GP-dependent entry, Vero cells were pretreated with ammonium
chloride (NH4Cl), which neutralizes endo/lysosomal acid pH, and
exposed to rVSV-LLOV-GP. No infection was observed in cells
pretreated with NH4Cl, compared to the untreated control
(Fig. 3). Therefore, the entry requirement for endo/lysosomal acid
pH remains a shared feature of all known ﬁloviruses.
2.5. Endosomal cysteine proteases are essential host factors for LLOV
GP-dependent entry
Cysteine cathepsins, a class of endosome/lysosome-resident
host cysteine proteases (Turk et al., 2012), are broadly required
for ﬁlovirus entry and infection, and cathepsin B (CatB) plays
a speciﬁc viral isolate-dependent role (Chandran et al., 2005; Misasi
et al., 2012; Schornberg et al., 2006; Wong et al., 2010). Cleavage
of GP by cysteine cathepsins removes the Muc domain and glycan
cap (Bale et al., 2011; Chandran et al., 2005; Dube et al., 2009; Hood
et al., 2010; Lee et al., 2008), generating an intermediate that
can now recognize the intracellular entry receptor, NPC1 (Miller
et al., 2012) and is presumed to be fusion-competent (Brecher et al.,
2012) (Wong, Miller, and Chandran, unpublished). In addition to
carrying out this priming step, endosomal cysteine cathepsins are
proposed to play a role in the fusion triggering process itself
(Chandran et al., 2005).
Previous work illustrated this cysteine cathepsin requirement
through the use of the Clan CA cysteine protease inhibitor E-64,
which effected a 499% reduction in infection mediated by glyco-
proteins from EBOV, Taï forest virus (TAFV), Sudan virus (SUDV),
Reston virus (RESTV), and Marburg virus (MARV) (Chandran et al.,
2005; Misasi et al., 2012). Accordingly, we pretreated Vero cells with
either E-64 or the vehicle DMSO, and exposed them to rVSV-EBOV-
GP and rVSV-LLOV-GP (Fig. 4A). Both viruses were similarly sensi-
tive to E-64 treatment, providing evidence that LLOV GP, like all
other known ﬁlovirus glycoproteins, requires endosomal cysteine
cathepsin activity to mediate viral entry.
2.6. Cathepsin B is dispensable for LLOV GP-dependent entry
Although all known ﬁloviruses (including LLOV) require host
cysteine cathepsins for entry as shown above, the requirement for
CatB varies by virus. In general, CatB activity plays an important
role in entry by EBOV, BDBV, and TAFV, but not by SUDV, RESTV,
and MARV (Misasi et al., 2012). The molecular bases of these
differences in protease dependence remain incompletely deﬁned,
but relate at least in part to sequence polymorphisms that
modulate GP1–GP2 interactions and the stability of the trimeric
GP pre-fusion spike (Wong et al., 2010) (also see Fig. S2). The
requirements for speciﬁc cysteine cathepsins in viral multiplica-
tion in vivo may be more complex, however, since EBOV can infect
and kill CatB-knockout mice (Marzi et al., 2012). Whether this is
due to the use of alternative proteases or generation of CatB-
independent GP variants through mutation (as observed in vitro
(Wong et al., 2010)), remains to be determined.
To determine if LLOV GP requires CatB to mediate viral entry, at
least in tissue culture, we pretreated Vero cells with the Clan CA
protease inhibitor CA074 under conditions that afford selective
inhibition of CatB, as described previously (Chandran et al., 2005;
Wong et al., 2010). We then challenged these cells with rVSV-
EBOV GP and rVSV-LLOV GP. As expected, CA074 reduced EBOV
GP-dependent infection by E90%; however, little or no reduction
was observed in LLOV GP-dependent infection (Fig. 4B). Therefore,
CatB is dispensable for viral entry mediated by LLOV GP.
2.7. Proteolytic cleavage of LLOV GP in vitro generates a primed entry
intermediate
Cleavage of the trimeric GP spike derived from both ebola-
viruses and marburgviruses by endosomal cysteine cathepsins
in vitro, or by surrogate enzymes such as thermolysin, results in
the generation of a GP trimer lacking GP1 sequences correspond-
ing to the Muc domain and the glycan cap (Chandran et al., 2005;
Dube et al., 2009; Hood et al., 2010; Lee et al., 2008; Schornberg
et al., 2006). This cleaved GP intermediate (GPCL), which is
competent to bind to the ﬁlovirus receptor NPC1 (Côté et al., 2011;
Miller et al., 2012), is proposed to resemble one or more GP species
generated within the endocytic pathway during viral entry. The
requirement of endosomal cysteine protease activity for LLOV GP-
dependent entry suggested that LLOV GP also undergoes cleavage
to generate such an entry intermediate.
To test this hypothesis directly, we incubated rVSV-LLOV-GP
particles with increasing concentrations of the bacterial metallo-
protease thermolysin, which mimics the action of CatBþCatL on
EBOV GP (Schornberg et al., 2006). Like EBOV GP1, LLOV GP1 was
cleaved by thermolysin to generate an E17 kDa intermediate
containing its N-terminal E190 amino acid residues. This
sequence, highly conserved among ﬁloviruses, constitutes the
‘base’ subdomain of GP1, which is covalently and non-covalently
associated with GP2, and the ‘head’ subdomain, which contains
the NPC1-binding site (Dias et al., 2011; Lee et al., 2008). Strikingly,
the LLOV GPCL intermediate was generated at substantially lower
Fig. 3. LLOV GP-mediated entry requires endosomal acid pH. Vero cells were
pretreated with ammonium chloride (20 mM), and then exposed to rVSVs bearing
VSV G or ﬁlovirus glycoproteins. Infected cells were visualized by ﬂuorescence
microscopy at 12–16 h post-infection. Averages7SD (n¼4) are shown. npo0.05.
nnnpo0.001.
Fig. 4. Cysteine cathepsin activity is required for LLOV GP-dependent entry, but
cathepsin B (CatB) is dispensable. (A–B) Vero cells were pre-treated with 1% DMSO
(vehicle control), the broad-spectrum cysteine cathepsin inhibitor E-64 (300 mM)
(A), or the CatB-selective inhibitor CA074 (B) for 4 h at 37 1C, and then exposed to
rVSVs bearing EBOV or LLOV GP. Infected cells were visualized by ﬂuorescence
microscopy at 12–16 h post-infection. Averages7SD (n¼4) are shown. npo0.05.
nnpo0.01. nnnpo0.001. ns, not signiﬁcant.
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protease concentrations than its EBOV counterpart, indicating that
LLOV GP is much more sensitive to proteolytic cleavage than EBOV
GP (Fig. 5).
2.8. LLOV GPCL cannot bypass the entry requirement for endosomal
cysteine protease activity
While in vitro-generated EBOV and MARV GPCL can recognize
the endosomal receptor NPC1 and bypass requirements for speciﬁc
endosomal cysteine proteases (e.g., CatB for EBOV), they remain
susceptible to a broad-spectrum inhibitor of clan CA cysteine
proteases, such as E-64 (Fig. 6) (Chandran et al., 2005;
Schornberg et al., 2006; Wong et al., 2010). These ﬁndings suggest
that additional proteolytic cleavage events, possibly coupled to a
late step in the entry process, are required for ebolavirus and
marburgvirus entry. To determine if LLOV GPCL also requires these
additional cleavage events, or if it can instead fully bypass the
requirement for endosomal cysteine proteases, we exposed
cleaved rVSV-LLOV GPCL particles to cells pre-treated with E-64
(Fig. 6). Like its EBOV counterpart, rVSV-LLOV GPCL remained
susceptible to E-64, indicating that all known ﬁlovirus entry
mechanisms must undergo one or more additional cysteine-
protease dependent steps that remain to be deﬁned.
2.9. LLOV GP-dependent entry requires the ﬁlovirus receptor,
Niemann–Pick C1 (NPC1)
NPC1, a multipass membrane protein localized to late endo-
somes and involved in endosomal cholesterol trafﬁcking (Carstea
et al., 1997; Cruz et al., 2000; Davies et al., 2000), is a critical host
factor for entry, infection, and pathogenesis by ebolaviruses and
marburgviruses (Carette et al., 2011; Côté et al., 2011; Krishnan
et al., 2012; Miller et al., 2012). Genetic loss of NPC1 function
causes Niemann–Pick type C (NPC) disease in humans (Patterson
et al., 2001; Walkley and Suzuki, 2004). To test if LLOV resembles
other ﬁloviruses in its requirement for NPC1, we exposed primary
skin ﬁbroblasts derived from NPC patients to rVSV-EBOV GP and
rVSV-LLOV GP (Fig. 7A). We observed little or no infection with
either virus in these NPC1-hypomorphic cells, whereas ﬁbroblasts
derived from a healthy individual were highly susceptible. Ectopic
expression of WT human NPC1 in the NPC ﬁbroblasts could confer
full levels of EBOV GP- and LLOV GP-dependent infection (Fig. 7A).
Similar results were obtained in a Chinese hamster ovary (CHO)
cell line fully deﬁcient for NPC1 (Fig. 7B). These ﬁndings provide
evidence that LLOV, like all other known ﬁloviruses, requires NPC1
for cell entry and infection.
2.10. Cleaved LLOV GP binds with high afﬁnity to the second luminal
domain of NPC1.
Current evidence indicates that NPC1 is an endosomal receptor
for ﬁloviruses and marburgviruses that speciﬁcally and directly
recognizes cleaved forms of ebolavirus and marburgvirus GP
(GPCL) (Krishnan et al., 2012; Lee et al., 2013; Miller et al., 2012)
(Ndungo, Wec, and Chandran, unpublished). Moreover, we showed
that this virus-receptor interaction is mediated by the second
luminal domain of NPC1, domain C (Krishnan et al., 2012; Miller
et al., 2012). To determine if LLOV GP can also directly recognize
NPC1, we tested its capacity to capture puriﬁed human NPC1
domain C in an ELISA (Fig. 7C). As reported previously for
uncleaved EBOV GP, uncleaved LLOV GP did not appear to interact
with NPC1 domain C. In contrast, LLOV GPCL, like its EBOV GPCL
counterpart, could speciﬁcally capture NPC1 domain C (Fig. 7C).
Interestingly, LLOV GPCL bound to human NPC1 with a higher
apparent afﬁnity than did EBOV GPCL (binding EC50 of
0.1470.04 nM vs. 0.5070.1 nM, respectively). These results show
that NPC1 is a critical entry receptor for LLOV, and raise the
possibility that it is a universal ﬁlovirus receptor.
2.11. Properties of LLOV secreted glycoproteins: LLOV Δ-peptide
blocks ﬁlovirus GP-dependent entry
In addition to the viral spike glycoprotein, the genomes of
ebolaviruses, but not marburgviruses, encode two secreted glyco-
proteins that are not incorporated into viral particles–sGP and
Δ-peptide (Sanchez et al., 1998; Volchkova et al., 1998; 1999).
EBOV sGP shares its ﬁrst 295 amino acid residues with the viral
spike GP, but possesses a unique, highly O–glycosylated, C-
terminal sequence. It is synthesized as a precursor, pre-sGP, which
is translocated into the ER and transported to the Golgi apparatus,
where it undergoes cleavage by furin. This cleavage step generates
the mature sGP monomer and a small secreted peptide,Δ-peptide.
Recent work suggests that sGP may serve as an immunologic
decoy that redirects the host immune system away from neutra-
lizing epitopes in the viral spike glycoprotein (Mohan et al., 2012).
We previously found that the Δ-peptide could inhibit ﬁlovirus
entry in tissue culture (Radoshitzky et al., 2011). However, the
mechanism by which Δ-peptide inhibits viral entry and the
physiological signiﬁcance of this activity remain unknown.
Examination of the LLOV genome sequence indicated that it
resembles ebolaviruses in encoding sGP and Δ-peptide. Accord-
ingly, we expressed and puriﬁed a recombinant form of LLOV
Δ-peptide fused to the fragment crystallizable region (Fc) of a
human IgG1 (LLOV-Δ-Fc) (Fig. 8A), and examined its capacity to
inhibit ﬁlovirus entry (Fig. 8B). Vero cells were pre-incubated with
increasing concentrations of LLOV-Δ-Fc, and then exposed to
Moloney murine leukemia virus pseudotypes bearing MARV GP.
LLOV-Δ-Fc efﬁciently inhibited MARV GP-dependent entry, as
Fig. 5. LLOV GP1 is rapidly cleaved to a primed E17 kDa species (GP1CL) in vitro.
rVSVs bearing LLOV GP or EBOV GP were exposed to thermolysin (0, 6.25, 12.5, 25,
50, 100, 200 mg/ml) for 1 h at 37 1C. Enzyme digestion was stopped with phosphor-
amidon (0.5 mM) and GP1 was visualized by western blotting with peptide-speciﬁc
antisera that detect an N-terminal region of GP1 (residues 83–97).
Fig. 6. Cleaved LLOV GP cannot overcome the entry requirement for endosomal
cysteine cathepsins. Vero cells were pre-treated with 1% DMSO (control) or E-64
(300 mM) for 4 h at 37 1C, and then exposed to rVSVs bearing uncleaved (GP) or
thermolysin-cleaved GP proteins (GPCL). Infected cells were visualized by ﬂuores-
cence microscopy at 12–16 h post-infection. Averages7SD (n¼2) from a repre-
sentative experiment are shown.. npo0.05. nnnpo0.001.
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described previously for its counterpart derived from an ebola-
virus (SUDV-Δ-Fc) (Fig. 8B). Thus, LLOV resembles ebolaviruses not
only in the organization of its GP gene, but also in the functional
activity of one of the secreted glycoproteins that these viruses
share with each other, but not with marburgviruses.
3. Discussion
Lloviu virus (LLOV) is the founding member of the Cuevavirus
genus in the family Filoviridae. Described in 2011, it is the ﬁrst
ﬁlovirus known that may be virulent in bats, and possibly the ﬁrst
known ﬁlovirus endemic to Europe (Negredo et al., 2011). Here, we
demonstrate that the viral spike glycoprotein and small secreted
glycoprotein (Δ-peptide) of LLOV, while divergent from those of
other ﬁloviruses in sequence and antigenicity, nevertheless closely
resemble them in both structure and function.
The position of the polybasic recognition site for furin, which
post-translationally cleaves the GP0 precursor to GP1þGP2 sub-
units, differs among ﬁlovirus GP proteins. While it is located at the
C-terminal end of the mucin-like (Muc) domain in ebolaviruses, the
furin site is positioned within this domain in marburgviruses (Fig.
S1). Thus, Muc is contained entirely within GP1 in ebolaviruses, but
is divided between GP1 and GP2 in marburgviruses. Interestingly,
like MARV GP, LLOV GP is predicted to undergo furin cleavage within
Muc (Fig. S1). The portion of Muc at the N–terminus of LLOV GP2
may play a role in stabilizing the GP1–GP2 trimer interface and and/
or protecting it from antibody neutralization, as proposed for MARV
GP (Erica O. Saphire, personal communication).
As shown previously for ebolaviruses and marburgviruses, and
by Maruyama and co-workers for LLOV, LLOV GP-dependent entry
requires both endosomal acid pH and the activity of cysteine
cathepsins, a group of papain-superfamily proteases active in
endo/lysosomal compartments (Fig. 3 and Fig. 4A) (Chandran
et al., 2005; Misasi et al., 2012; Takada et al., 1997; Wool-Lewis
and Bates, 1998). However, like RESTV and MARV (Misasi et al.,
2012), LLOV does not require the activity of a speciﬁc enzyme,
cathepsin B (CatB), implicated in entry by EBOV, BDBV, and TAFV
(Fig. 4B). We previously showed that changes in amino acid
residues near the N–terminus of GP1, and at or near the GP1–GP2
intersubunit interface afford CatB-independent entry by EBOV
(Wong et al., 2010). One such residue is amino acid 47 in GP1,
which is Asp in CatB-dependent GP proteins, and Glu or Val in CatB-
independent GP proteins (Glu in SUDV, RESTV, and MARV; Val in
LLOV) (Fig. S2). Both Asp 47-Glu and Asp 47-Val render EBOV
CatB-independent (Misasi et al., 2012) (Sandesara, Wong, and
Chandran, unpublished), strongly suggesting that this sequence
polymorphism is at least partly responsible for CatB-independent
entry mediated by LLOV GP.
Cysteine cathepsins are required for ﬁlovirus entry at least in
part because they cleave GP1 to remove surface-exposed C-terminal
sequences (Muc and glycan cap) (Chandran et al., 2005; Dube et al.,
2009; Lee et al., 2008; Schornberg et al., 2006). GP cleavage
unmasks the receptor-binding site in GP1 (see below) (Lee et al.,
2008; Miller et al., 2012), and likely alleviates both covalent and
non-covalent constraints on GP rearrangement during viral mem-
brane fusion (Brecher et al., 2012; Dube et al., 2009; Wong et al.,
2010). We found that LLOV GP also undergoes cleavage in vitro to
generate an intermediate (GPCL) comprising the conserved struc-
tural core of the GP1–GP2 trimer. Interestingly, however, LLOV GP
resembled MARV GP in being much more protease-sensitive than
EBOV GP (Fig. 5) (Miller et al., 2012) (Wec and Chandran, unpub-
lished). LLOV GP thus exempliﬁes the tendency for CatB-
independent ﬁlovirus glycoproteins to be more susceptible to
proteolytic cleavage than their CatB-dependent counterparts, sug-
gesting that protease requirements during ﬁlovirus entry
are linked to the conformational ﬂexibility of the GP pre-fusion
spike. While the selective forces that set the balance between
GP-dependent viral stability and infectivity remain undeﬁned, these
ﬁndings raise the possibility that LLOV (and MARV) might be able to
enter and infect tissues with low levels of cysteine protease activity
more efﬁciently than can EBOV. Alternatively, the variations in host
protease dependence and sensitivity observed among ﬁlovirus
Fig. 7. Niemann–Pick C1 (NPC1) is an essential entry receptor for LLOV. (A) Primary
NPC1-mutant human ﬁbroblasts from Niemann–Pick type C disease patients
(NPC1mut), NPC1mut ﬁbroblasts engineered to express WT human NPC1
(NPC1mutþhuNPC1), and ﬁbroblasts from control individuals were exposed to rVSVs
bearing LLOV or EBOV GP. Infected cells were visualized by ﬂuorescence microscopy
at 12–16 h post-infection. Averages7SD (n¼4) are shown. (B) NPC1-deﬁcient
Chinese hamster ovary (CHO) cells and NPC10 cells engineered to express human
NPC1 (NPC10þhuNPC1) were exposed to rVSVs bearing LLOV or EBOV GP. Infected
cells were visualized by ﬂuorescence microscopy at 12–16 h post-infection. Aver-
ages7SD (n¼4) are shown. (C) Cleaved LLOV GP recognizes the second luminal
domain (C) of NPC1. Biotin-labeled rVSVs bearing uncleaved or cleaved ﬁlovirus
glycoproteins were captured onto streptavidin-coated plates, and binding of puriﬁed
FLAG-tagged NPC1 domain C was detected by ELISA with an anti-FLAG antibody
conjugated to horseradish peroxidase. nnpo0.01. nnnpo0.001. nnnnpo0.0001. ns, not
signiﬁcant. o , measurement below the threshold of detection.
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glycoproteins may simply be collateral effects of other adaptive
changes in GP (driven by host immune pressure, for example).
Previous work showed that in vitro GP-GPCL cleavage does not
bypass the entry requirement for cysteine cathepsin activity, at
least for ebolaviruses and marburgviruses (Chandran et al., 2005;
Schornberg et al., 2006; Wong et al., 2010). Here, we demonstrate
that LLOV GP fully resembles other ﬁlovirus glycoproteins in this
respect (Fig. 6). Because VSVs containing EBOV GPCL arrest in late
endosomal compartments in cells bereft of cysteine cathepsin
activity (Chandran, data not shown), current evidence suggests the
existence of at least one cysteine protease-dependent step in
ﬁlovirus entry downstream of GP-GPCL cleavage. This enigmatic
protease-dependent late step in entry thus appears to be shared by
all known ﬁloviruses.
In this study, we demonstrated that LLOV GP-dependent entry
also requires the ebolavirus and marburgvirus receptor NPC1, and can
utilize the human ortholog of this protein (Fig. 7A and B). Moreover,
like all other ﬁloviruses examined to date (Krishnan et al., 2012;
Miller et al., 2012), LLOV GPCL, but not uncleaved GP, bound directly to
the second luminal domain of NPC1, domain C. Unexpectedly, the
afﬁnity of LLOV GPCL for human NPC1 appeared to be greater than
that of the corresponding interaction between EBOV GPCL and NPC1
(Fig. 7C). These ﬁndings suggest that the virus-NPC1 interaction
would not impose a barrier to infection of humans and non-human
primates by LLOV. Finally, we note that while we have examined only
human NPC1 in this report, studies of the interaction between
Schreibers's long-ﬁngered bat NPC1 and the glycoproteins of LLOV
and other ﬁloviruses are also warranted, because they may reveal
host species- and virus-dependent differences in the nature and
strength of the ﬁlovirus-receptor interaction, with potential implica-
tions for LLOV's virulence in a bat host. Indeed, such a difference
might explain the intriguing observation that LLOV GP-dependent
entry is relatively more efﬁcient in a Schreibers's long-ﬁngered bat
cell line (Maruyama et al., 2013). Taken together, our work supports
the hypothesis that NPC1 is a universal receptor for ﬁloviruses.
4. Materials and methods
4.1. Cells and viruses
Vero African grivet kidney cells, 293T human embryonic
kidney cells, and human primary ﬁbroblasts from control indivi-
duals (GM05659) or Niemann–Pick disease patients (GM18436)
(Coriell Institute for Medical Research) were maintained in
Dulbecco's modiﬁed Eagle medium (DMEM) (Life Technologies,
Grand Island, NY) supplemented with 10% fetal bovine serum
(FBS; Atlanta Biologicals, Flowery Branch, GA) and 1% penicillin-
streptomycin (Life Technologies). Niemann–Pick C1 (NPC1)-null
Chinese hamster ovary (CHO) ﬁbroblasts (M12 line), a kind gift of
Dr. Dan Ory, were maintained in DMEM-F-12 media (50–50 mix)
(Corning, Manassas, VA), supplemented with 10% FBS, and 1%
penicillin-streptomycin. Human ﬁbroblasts and CHO M12 cells
stably expressing human NPC1-FLAG were generated by retroviral
transduction, as previously described (Carette et al., 2011; Miller
et al., 2012). Furin-deﬁcient CHO cells (FD11), a kind gift of Dr.
Margaret Kielian, were maintained in minimal essential medium
(MEM)-alpha (Life Technologies) supplemented with 10% FBS,
penicillin-streptomycin and 1% glutamine (Life Technologies). All
cell lines were maintained at 37 1C, 5% CO2 in a humidiﬁed
incubator.
DNA encoding the LLOV GP gene was synthesized according to
Genbank accession number JF828358, except that the sequence
was codon-optimized for mammalian cell expression and the
AAAAAAA sequence at nucleotide positions 910–916 in the GP
open reading frame (complementary to the U7 stutter sequence in
the viral genome sequence) was mutated to AAGAAGAA. These
changes afforded constitutive production of the full-length viral
spike glycoprotein (GP1,2; hereafter referred to as GP). Nucleotide
and amino acid sequences for the ﬁnal LLOV GP expression
construct are available as supplementary data. A recombinant
VSV (rVSV) encoding enhanced green ﬂuorescent protein (eGFP)
and LLOV GP in place of VSV G was rescued from cDNA as
described previously (Whelan et al., 1995; Wong et al., 2010).
Plaque-puriﬁed rVSV-LLOV GP clones were ampliﬁed in Vero cells,
concentrated by pelleting through 10% sucrose cushions, and
stored in aliquots at 80 1C. rVSVs bearing EBOV and MARV GP
were described previously (Miller et al., 2012; Wong et al., 2010).
Sequencing the cDNA corresponding to the GP-coding region
within the genomes of these viral particles conﬁrmed that no
nucleotide changes had occurred during virus recovery and
ampliﬁcation. All experiments with rVSVs were performed using
enhanced biosafety level 2 procedures approved by the Einstein
Institutional Biosafety Committee. VSV pseudotypes expressing
eGFP and bearing VSV G or ﬁlovirus GP were generated as
described previously (Takada et al., 1997).
4.2. Viral infectivity measurements
Single-cycle VSV infectivity measurements were carried out as
described previously (Wong et al., 2010). Brieﬂy, conﬂuent mono-
layers of cells were exposed to a series of dilutions of each virus-
containing sample (in DMEM with 2% FBS) for 1 h at 37 1C.
Ammonium chloride (20 mM ﬁnal) was then added to inhibit viral
spread (for rVSVs only). eGFP-positive infected cells were manu-
ally enumerated by ﬂuorescent microscopy at 14–16 h post-
infection. Fluorescent focus-forming assays were performed, and
viral infection foci were quantiﬁed, as described previously (Wong
et al., 2010).
Retroviral pseudotypes were produced as previously described
(Radoshitzky et al., 2011). Brieﬂy, HEK 293T cells were transfected
with (1) a plasmid expressing MARV GP; (2) the pQCXIX vector
(Clontech) expressing enhanced green ﬂuorescent protein (eGFP)
ﬂanked by the Moloney murine leukemia virus (MoMLV) long
terminal repeats; and (3) a plasmid encoding the MoMLV gag-pol
genes. Virus-containing cell supernatants were collected at 48 h
post-transfection and ﬁltered to remove cellular debris. Cells were
exposed to MoMLV-MARV GP for 5 h, and then washed and
replenished with fresh medium. After 48 h post-transduction, cells
were detached and ﬁxed. The percentage of eGFP-positive cells
(% of cells transduced) was measured by ﬂow cytometry (10,000
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Fig. 8. Secreted LLOV glycoprotein, Δ peptide, inhibits LLOV GP-mediated entry.
(A) Recombinant LLOV and SUDV Δ-peptides fused to the Fc sequence of an
immunoglobulin G were expressed and puriﬁed by protein A afﬁnity chromato-
graphy, and visualized by SDS-PAGE and Coomassie Blue staining. (B) Vero cells
were treated with LLOV or SUDV Δ-Fc in increasing concentrations in the presence
of eGFP-expressing Moloney murine leukemia virus particles bearing MARV GP.
Cells were detached at 48 h post-transduction, and the percentage of eGFP-positive
cells was measured by ﬂow cytometry. Averages7SD (n¼3) are shown. nnpo0.01.
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events; BD LSR Fortessa, San Jose, CA). FlowJo software (Tree Star
Inc., San Carlos, CA) was used for data analysis.
4.3. Production of a polyclonal antibody to LLOV GP1
A polyclonal antiserum was generated in a rabbit by immuni-
zation with a peptide corresponding to residues 84–98 of LLOV GP
(TKRWGFRSDVIPKIV), conjugated to keyhole limpet hemocyanin
(KLH) (Paciﬁc Immunology, Ramona, CA). A polyclonal antiserum
to the corresponding peptide from EBOV GP has been described
previously (Misasi et al., 2012).
4.4. SDS-PAGE and western blotting
Virus-containing samples were resolved in 12% sodium dodecyl
sulfate (SDS)-polyacrylamide gels, and proteins were transferred
to a nitrocellulose membrane. The LLOV GP1 subunit was detected
using the polyclonal antibody described above (1:10,000 dilution),
followed by incubation with a secondary antibody, donkey anti-
rabbit immunoglobulin G (IgG) conjugated to horseradish perox-
idase (1:10,000 dilution; Santa Cruz Biotechnology Inc., Santa
Cruz, CA). Bands were detected using an enhanced chemilumines-
cence reagent (Thermo Fisher Scientiﬁc; Rockford, IL), followed by
exposure to X-ray ﬁlm. In some experiments, viral proteins were
deglycosylated using peptide N-glycosidase F (PNGase F, New
England Biolabs, Ipswich, MA), according to the manufacturer's
instructions. NPC1-FLAG expression in CHO M12 cells was
assessed by western blotting of cell lysates resolved in 8% SDS-
polyacrylamide gels with an HRP-conjugated anti-FLAG antibody
conjugate (1:10,000; Sigma-Aldrich, St Louis, MO).
4.5. Protease inhibitor treatments
Cysteine protease inhibitors CA074 [N-(L-3-trans-propylcarba-
moyloxirane-2-carbonyl)-Ile-Pro-OH] and E-64 [L-trans-epoxysucci-
nyl-leucyl-amide-(4-guanido)-butane] (Wako Chemicals, Richmond,
VA) were dissolved in dimethyl sulfoxide (DMSO) and dispensed
into culture medium immediately before use. To inhibit protease
activity in cells, monolayers were incubated with drug-containing
media at 37 1C for 4 h prior to virus infection.
4.6. Protease digestion reactions
To examine the sensitivity of rVSV-LLOV-GP to proteolysis,
aliquots of concentrated virus were incubated with various
amounts of thermolysin (THL; 0–200 mg per ml; Sigma-Aldrich)
for 1 h at 37 1C. Reactions were carried out in NT buffer (10 mM
Tris.Cl [pH 7.5], 135 mM NaCl), and stopped by adding phosphor-
amidon (0.5 mM; Peptide International, Louisville, KY) and placing
on ice for 15 min.
4.7. GP-NPC1 binding ELISAs
rVSV-LLOV-GP was modiﬁed using a functional-spacer-lipid
reagent conjugated with biotin (FSL-biotin, Sigma) at 37 1C for
1 h. The biotin-labeled virions were then captured onto high-
binding 96-well plates (Corning) previously coated with strepta-
vidin (0.65 μg per mL in PBS) and blocked with PBS containing 3%
bovine serum albumin (PBSA). Prior to capture, virions were either
left untreated or incubated with thermolysin (12.5 μg per mL at
37 1C for 1 h) to generate rVSV-LLOV GPCL. After washing to
remove unbound virus, serial dilutions of puriﬁed, FLAG-tagged
human NPC1 domain C (domain C; 0–40 μg per mL) were added.
Bound domain C was detected with an HRP-conjugated anti-FLAG
antibody (Sigma-Aldrich), and Ultra-TMB substrate (Thermo
Fisher). Half-maximal binding concentrations (EC50) values were
calculated by nonlinear regression analysis of normalized binding
curves in Prism (GraphPad Software, La Jolla, CA). All ELISA
incubation steps were done at 37 1C for 1 h or at 4 1C overnight.
Each dataset for curve ﬁtting included at least two technical
replicates per domain C concentration, and EC50 values were
computed from at least two independent experiments.
4.8. Generation of a puriﬁed LLOV Δ-peptide-Fc fusion protein
LLOV or control SUDV Δ-peptide fused to the fragment crystal-
lizable region (Fc) of human IgG1 was produced and puriﬁed as
described previously (Radoshitzky et al., 2011). Brieﬂy, HEK 293T
cells were transfected with expression plasmids encoding LLOV or
SUDV Δ-Fc and grown in 293 SFM II medium (Invitrogen). Super-
natants were collected 48 h later and proteins were bound to
a protein A-sepharose Fast Flow bead matrix (GE Healthcare). After
washing, proteins were eluted with 50 mM sodium citrate-50 mM
glycine, pH 2, followed by neutralization with NaOH, dialyzed
against PBS, concentrated, and quantiﬁed.
4.9. Transmission electron microscopy
Vero E6 cells were transfected using X-tremeGENE HP DNA
Transfection Reagent (Roche) with a PJ603 plasmid expressing
LLOV GP and a pCAGGS plasmid expressing FLAG-tagged LLOV
VP40 (1:1 ratio), to generate virus-like particles (VLPs). 72 h later,
supernatants were removed and cells were ﬁxed with 2.5%
glutaraldehyde (E.M. Sciences, Warrington, PA) in Millonig's
sodium phosphate buffer (Tousimis Research, Rockville, MD) for
20 min, scraped, and spun down at 500 xg for 10 min at 4 1C. The
pellet was ﬁxed for 24 h at 4 1C, and then post-ﬁxed with 1%
osmium tetroxide (E.M. Sciences) and staining en bloc with 2%
uranyl acetate. Samples were dehydrated with ethanol and
embedded into Spurr plastic resin (E.M. Sciences). Two hundred
mesh copper grids were used to mount 60–80 nm sample sections,
sliced with a Leica UC7 ultramicrotome. Mounted grids were
stained with lead citrate before examination on a FEI G2 Tecnai
transmission electron microscope.
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